GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences …

– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset epilepsy –

– Both doses significantly reduced drop seizure frequency in patients with poor seizure control despite the use of multiple anti-epileptic drugs –

LONDON and CARLSBAD, Calif., May 16, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of cannabidiol oral solution in patients with Lennox-Gastaut syndrome (LGS), a rare, severe and difficult to treat form of childhood-onset epilepsy.1 Cannabidiol oral solution (CBD, Epidiolex®), is a pharmaceutical formulation of highly purified cannabidiol a cannabinoid lacking

... read more at: http://www.globenewswire.com/news-release/2018/05/16/1507763/0/en/GW-Pharmaceuticals-and-U-S-Subsidiary-Greenwich-Biosciences-Announce-Publication-in-The-New-England-Journal-of-Medicine-of-a-Phase-3-Study-of-Cannabidiol-Oral-Solution-in-Lennox-Ga.html

Leave a Reply